Indian journal of ophthalmology · 2025
Reper intraocular lens with artificial iris: Presentation and outcomes in patients with significant iris defects and Aphakia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gomel Nir, Shemesh Nadav, Lavi Itai, Achiron Asaf, Mimouni Michael, Sorkin Nir, Cohen Eyal, Verssano David, Levinger Eliya
Аннотация
PURPOSE: The Reper device (Reper-NN LTD, Nizhny Novgorod, Russia), an acrylic iris diaphragm combined with an intraocular lens (IOL), may be adapted for patients with various iris defects and aphakia. We aim to present our experience using the Reper artificial iris-IOL device.
SETTING: Tertiary medical center.
METHODS: This study includes patients who underwent implantation of the Reper artificial iris-IOL device at a single tertiary medical center between 2017 and 2023. The non-parametric signed test was used to compare preoperative and postoperative outcomes.
RESULTS: Fifteen patients with aphakia and partial aniridia were included (four females [27%], mean age: 68.3). Mean follow-up time was 7.87 ± 5.62 months (range: 1-20). Following surgery, 87% (13 patients) showed improvement in corrected distance visual acuity (CDVA), while 13% (two patients) maintained their preoperative CDVA. The mean improvement in CDVA was 0.68 ± 0.19 logMAR (P value = 0.0015 [95% confidence interval (CI): 0.28-1.08. Unpaired t-test]). Moreover, all patients (100%) expressed complete satisfaction with postoperative cosmetic outcomes.
CONCLUSION: This study represents the largest reported series on Reper artificial iris-IOL implantation procedure and provides initial insights into its outcomes. No surgical complications were reported, and most patients experienced VA improvement and cosmetic satisfaction. These findings may assist ophthalmic surgeons in evaluating the benefits and risks of this implant. Larger, longer-term studies are needed to better establish its safety and efficacy.
SETTING: Tertiary medical center.
METHODS: This study includes patients who underwent implantation of the Reper artificial iris-IOL device at a single tertiary medical center between 2017 and 2023. The non-parametric signed test was used to compare preoperative and postoperative outcomes.
RESULTS: Fifteen patients with aphakia and partial aniridia were included (four females [27%], mean age: 68.3). Mean follow-up time was 7.87 ± 5.62 months (range: 1-20). Following surgery, 87% (13 patients) showed improvement in corrected distance visual acuity (CDVA), while 13% (two patients) maintained their preoperative CDVA. The mean improvement in CDVA was 0.68 ± 0.19 logMAR (P value = 0.0015 [95% confidence interval (CI): 0.28-1.08. Unpaired t-test]). Moreover, all patients (100%) expressed complete satisfaction with postoperative cosmetic outcomes.
CONCLUSION: This study represents the largest reported series on Reper artificial iris-IOL implantation procedure and provides initial insights into its outcomes. No surgical complications were reported, and most patients experienced VA improvement and cosmetic satisfaction. These findings may assist ophthalmic surgeons in evaluating the benefits and risks of this implant. Larger, longer-term studies are needed to better establish its safety and efficacy.